Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients

The first classification of angioedema without wheals was recently reported and comprises different forms of the disease distinguished by aetiology, mediator of oedema and inheritance.

[1]  M. Triggiani,et al.  Guidance for diagnosis and treatment of acute angioedema in the emergency department: consensus statement by a panel of Italian experts , 2014, Internal and Emergency Medicine.

[2]  S. Cichon,et al.  Enzymatic Assays for the Diagnosis of Bradykinin-Dependent Angioedema , 2013, PloS one.

[3]  P. Campo,et al.  Angioedema induced by angiotensin-converting enzyme inhibitors , 2013, Current opinion in allergy and clinical immunology.

[4]  M. Riedl,et al.  HAE update: special considerations in the female patient with hereditary angioedema. , 2013, Allergy and asthma proceedings.

[5]  P. Persson,et al.  The Kallikrein–Kinin system , 2012, Acta physiologica.

[6]  M. Cicardi,et al.  Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. , 2012, Allergy and asthma proceedings.

[7]  A. Linneberg,et al.  Epidemiology of non-hereditary angioedema. , 2012, Acta dermato-venereologica.

[8]  L. Bouillet,et al.  Safety and efficacy of icatibant self‐administration for acute hereditary angioedema , 2012, Clinical and experimental immunology.

[9]  J. Roberts,et al.  Angiotensin-converting enzyme (ACE) inhibitor angioedema: the silent epidemic. , 2012, The American journal of cardiology.

[10]  M. Cicardi,et al.  Hereditary angio-oedema , 2012, The Lancet.

[11]  J. Cronin,et al.  Treatment of an acute attack of type III hereditary angioedema with ecallantide. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  J. Fraj,et al.  Nonhistaminergic idiopathic angioedema: clinical response to icatibant. , 2012, Journal of investigational allergology & clinical immunology.

[13]  K. Bork,et al.  A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. , 2011, Clinical immunology.

[14]  R. Sotníková,et al.  Nitric oxide--the endothelium-derived relaxing factor and its role in endothelial functions. , 2010, General physiology and biophysics.

[15]  A. Kaplan.  Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. , 2010, The Journal of allergy and clinical immunology.

[16]  K. Binkley.  ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY REVIEW Open Access Factor XII mutations, estrogen-dependent , 2022 .

[17]  K. Bork.  Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[18]  P. Pundir,et al.  Comparison of the inhibitory effects of resveratrol and tranilast on IgE, 48/80 and substance P dependent-mast cell activation , 2010, Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology.

[19]  B. Guillot,et al.  Efficacy of tranexamic acid in sporadic idiopathic bradykinin angioedema , 2009, Allergy.

[20]  O. Fain.  [Acquired angioedema]. , 2010, La Revue de medecine interne.

[21]  K. Bork,et al.  Kallikrein–kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[22]  H. Schünemann,et al.  EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria , 2006, Allergy.

[23]  R. Lin,et al.  Increasing hospitalizations due to angioedema in the United States. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[24]  S. Cichon,et al.  Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. , 2006, American journal of human genetics.

[25]  M. Cicardi,et al.  Angioedema without urticaria: a large clinical survey , 2006, Canadian Medical Association Journal.

[26]  K. Bork,et al.  Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. , 2006, Biochemical and biophysical research communications.

[27]  K. Bork,et al.  Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex. , 2004, The American journal of medicine.

[28]  M. Cicardi,et al.  C1 inhibitor concentrate therapy in 473 patients with hereditary and acquired angioedema , 2004 .

[29]  K. Kragballe,et al.  Hereditary Angioedema. , 2018, The New England journal of medicine.

[30]  C. Drouet,et al.  Clinical and biological distinctions between type I and type II acquired angioedema. , 2003, The American journal of medicine.

[31]  M. Cicardi,et al.  Bradykinin-mediated angioedema. , 2002, The New England journal of medicine.

[32]  S. Choquet,et al.  Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. , 2000, The Journal of allergy and clinical immunology.

[33]  K. Binkley,et al.  Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. , 2000, The Journal of allergy and clinical immunology.

[34]  K. Bork,et al.  Hereditary angioedema with normal C1-inhibitor activity in women , 2000, The Lancet.

[35]  M. Cicardi,et al.  Idiopathic nonhistaminergic angioedema. , 1999, The American journal of medicine.

[36]  M. Cicardi,et al.  Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. , 1994, The Journal of allergy and clinical immunology.

[37]  E. Munch,et al.  Non‐Hereditary Angioedema Treated with Tranexamic Acid , 1985, Allergy.

[38]  A. Sheffer,et al.  Tranexamic acid therapy in hereditary angioneurotic edema. , 1972, The New England journal of medicine.